Preview

Опухоли женской репродуктивной системы

Расширенный поиск

Таксаны в адъювантной и неоадъювантной терапии рака молочной железы

https://doi.org/10.17650/1994-4098-2010-0-4-15-23

Полный текст:

Аннотация

В настоящее время таксаны (паклитаксел и доцетаксел) являются базовыми цитостатиками, применяющимися в лечении всех стадий рака молочной железы (РМЖ). Результаты проведенных и продолжающихся в настоящее время клинических исследований свидетельствуют о повышении эффективности лечения операбельного РМЖ при включении таксанов в режимы адъювантной и неоадъювантной химиотерапии и указывают на необходимость использования индивидуального подхода в зависимости от прогностических и предикторных факторов.

Об авторе

С. В. Лимарева
Отделение химиотерапии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Список литературы

1. Переводчикова Н.И., Портной С.М., Стенина М.Б., Анурова О.А.Гормонотерапия рака молочной железы. Пособие для врачей. М., 2010.

2. Высоцкая И.В., Летягин В.П., Абашин С.Ю., Погодина Е.М. Лечение ранних форм рака молочной железы. М., 2000.

3. Goldhirsch А.,Ingle J.,Gelber R. et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009;20(8):1319–29.

4. Божок А.А., Семиглазов В.Ф., Семиглазов В.В. и др. Факторы прогноза при раке молочной железы. Совр онкол 2005;7(1):4.

5. Blows F.M.,Driver K.E.,Schmidt M.K. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7(5):e100279.

6. Perou C., Eisen M., Hudis C. et al. Molecular portraits of human breast tumours. Nature 2009;406(6797): 747–52.

7. Горбунова В.А., Бесова Н.С. Значение таксанов в лечении рака молочной железы. Вопр онкол 2004;50(4).

8. Peto R. Оn behalf of the EBCTCG. SABCS, 2007.

9. Fourtzilas G.,Athanassiades A., Giannakakis T.et al. AphaseIIstudyof paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996;2:47–51.

10. Nabholtz J.M., Gelmon K., Bontenbal K. et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1558–67.

11. Bonneterre J., Spielman M., Guastalla J.P. et al. Efficacy and safety of docetaxel in heavily pretreated advanced breast cancer patients: the French Compassionate USE Programme Experience. Eur J Cancer 1999;35(10):1431–9.

12. Kruijtzer C., Verweij J., Schellens J. et al. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in the Netherlands. Anti-Cancer Drugs 2000;11(4):249–55.

13. Trandafir L., Chanine A., Spielman M. et al. Efficacy of taxotere in advanced breast cancer patients not eligible for further anthracyclines. Proc ASCO 1996; abstr 86.

14. Поддубная И.В. Достижения современной химиотерапии. Совр онкол 2003;5(2):49–58.

15. Gehl P., Boesgaard M., Paaske T. et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996;7:687–93.

16. Schwartsmann G., Menke C.H., Calefi M. et al. Phase II trial of taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer. Proc ASCO 1996;15:126; abstr 168.

17. Spielmann M., Zelek E., Dieras V. et al. A phase II study of Taxol and Epidoxorubicin as first-line chemotherapy in patients with metastatic breast carcinoma. Proc ASCO 2000; abstr 411.

18. Sparano J., O’Neill A., Shaefer P. et al. Phase II trial of doxorubicin and docetaxel plus granulocytocolonystimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group study E1196. J Clin Oncol 2000;18:2369–77.

19. Mavroudis D., Alexopoulos A., Ziras N. et al. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 2000;11:1249–54.

20. Viens P., Roche H., Kerbrat P. et al. Epirubicin–docetaxelcombinationinfirst-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. AmJClinOncol2001;24:328–35.

21. Milla-Santos A., Milla L., Rallo L. et al. High dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 2001;24:138–42.

22. HudisS., SeidmanA.,BaselgaL.etal. Sequential dose-dense doxorubicin, paclitaxel and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999;17:93–100.

23. Henderson I.C., Berry D.A., Demetri G.D. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicindoseinan adjuvantchemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2000;21:976–83.

24. Mamounas E.P. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node positive breast cancer. Proc ASCO 2003; abstr 12.

25. Thomas E., Buzdar A., Theriault R. et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary randomized clinical trial. Proc ASCO 2000;19:74; abstr 285.

26. Gianni L., Baselga J., Eiermann W. et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local regional disease. Proc ASCO 2002; abstr 132.

27. Piccart-Gebbart M., Procter M. et al. Trastuxumab after adjuvant chemotherapy in Her-2-positive breast cancer. N Engl J Med 2005;353:1659–72.

28. Romond E., Perez E. et al. Trastuxumab plus adjuvant chemotherapy for operable Her-2-positive breast cancer. N Engl J Med 2005;353:1673–84.

29. Buzdar A.U. et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412–7.

30. Green M.C., Buzdar A.U., Smith T. et al. Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathological complete remissiom rates when compared to every 3-week P therapy followed by FAC – final results of a prospective phase III randomized trial. Proc. ASCO 2002; abstr 135.

31. Pouillart P., Fumoleau P. et al. Final results of a phase II randomized parallel study of doxorubicin/cyclophosphamide and doxorubicin/ taxol as neoadjuvant treatment of local-regional breast cancer. J Clin Oncol 1999;17:3412–7.

32. Untch M., Konecny G., Ditsh N. et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc ASCO 2002; abstr133.

33. Chen X., Nie X. et al. Weekly paclitaxel plus carboplatin is an effective nonanthracyclin–containingregimenas neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010;21:961–7.

34. Boussen H., Cristofanilli M. et al. Phase II study to evaluate the efficasy of neoadjuvant lapatinib plus paclitaxel in patients with Inflamatory breast cancer. J Clin Oncol 2007;28:3248–55.

35. Martin M., Pienkowski T., Mackey J. et al. TAC improve disease free survival and overall survival over FAC in node positive early breast cancer patients: BCIRG 001: 55 months follow up. SABCS 2003; abstr 43.

36. Martin M., Lluch A. et al. Effect of docetaxel-basedadjuvantchemotherapyon disease-free survival in patients with high-risk node-negative breast cancer: results from the GEICAM 9805 trial. ASCO 2008; abstr 154.

37. Eietmann W., Pienkowsky T. et al. BCIR005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphsmide (TAC) versus doxorubicin and cyclophosphsmide followed by docetaxel (AC–T) in woman with Her-2/neu negative axillary lymph node positive early breast cancer. SABCS 2008; abstr 77.

38. Roche H., Fumoleau P. et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24(36):5664–71.

39. Jones S., Holmes F. et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/ cyclophosphamide is associated with an overa2ll survival benefit compared to doxorubicin/ cyclophosphamide andiswell-toleratedin woman 65 or older. SABCS 2007; abstr 17.

40. Slamon D., Eiermann W. et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC– T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (TCH) in Her-2 positive early breast cancer patients: BCIRG 006 study. SABCS 2006; abstr 52.

41. Smith J., Buyse M. et al. Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for Her-2-positive locally advanced breast cancer or as adjuvant therapy for Her- 2-positive pathologic stage III breast cancer: A phase II trial of the NSABP Foundation Research Group. ASCO 2010; abstr 580.

42. HeysS.,SarkarT.,HutcheonA.Docetaxel asadjuvantandneoadjuvant treatmentfor patients with breast cancer. Expert Opin Pharmacother 2004;5(10):2147–57.

43. BearH.,AndersonS.etal.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: Nationale Surgical Adjuvant Breast and Bowel ProjectProtocolB-27.JClinOncol 2006;24:2019–27.

44. Evans J., Yellowless A. et al. Phase III randomizedtrialofdoxorubicinanddocetaxel vs: an Anglo-Celtic Cooperative Oncology Group Study. J Clin Oncol 2005;23:2988–95.

45. Minckwitz J.-M., Raab G. et al. Doxorubicinwithcyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperativen treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676–85.

46. Steger G., Galid A. et al. Pathological complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocytecolony-stimulatingfactorin operablebreastcancer:resultsofABCSG–14. J Clin Oncol 2007;25:2012–8.

47. Семиглазов В.Ф. Перспективы лечения пациентов с Erb2 (Her-2)- позитивным раком молочной железы: клинические исследования. Материалы конференции «Белые ночи». СПб., 2008.

48. Blum J.L., Beveridge R., Robert N. et al. ABI-007 nanoparticle paclitaxel: demonstration of anti-tumor activity in taxanes-refractory metastatic breast cancer.Proc ASCO 2003;22; abstr 64.


Для цитирования:


Лимарева С.В. Таксаны в адъювантной и неоадъювантной терапии рака молочной железы. Опухоли женской репродуктивной системы. 2010;(4):15-23. https://doi.org/10.17650/1994-4098-2010-0-4-15-23

For citation:


Limareva S.V. Taxanes in adjuvant and neoadjuvant therapy for breast cancer. Tumors of female reproductive system. 2010;(4):15-23. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-4-15-23

Просмотров: 265


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)